01 4Reblozyl
02 2Reblozyl
Main Therapeutic Indication : Hematology
Currency : USD
2020 Revenue in Millions : 274
2019 Revenue in Millions : 0
Growth (%) : New Launch
Main Therapeutic Indication : Hematology
Currency : USD
2021 Revenue in Millions : 551
2020 Revenue in Millions : 274
Growth (%) : 101
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 166
2021 Revenue in Millions : 17
Growth (%) : 876
Main Therapeutic Indication : Hematology
Currency : USD
2022 Revenue in Millions : 717
2021 Revenue in Millions : 551
Growth (%) : 30
Main Therapeutic Indication : Hematology
Currency : USD
2023 Revenue in Millions : 1,008
2022 Revenue in Millions : 717
Growth (%) : 41
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 212
2022 Revenue in Millions : 166
Growth (%) : 28
